PMID- 34939424
OWN - NLM
STAT- MEDLINE
DCOM- 20220323
LR  - 20220323
IS  - 1744-8301 (Electronic)
IS  - 1479-6694 (Linking)
VI  - 18
IP  - 10
DP  - 2022 Mar
TI  - Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus 
      sunitinib in advanced renal cell carcinoma.
PG  - 1219-1234
LID - 10.2217/fon-2021-1109 [doi]
AB  - Aims: To assess grade 3/4 adverse events (AEs) and costs of first-line nivolumab 
      plus ipilimumab versus sunitinib in advanced or metastatic renal cell carcinoma. 
      Methods: Individual patient data from the all treated population in the CheckMate 
      214 trial (nivolumab plus ipilimumab, n = 547; sunitinib, n = 535) were used to 
      calculate the number of AEs. AE unit costs were obtained from US 2017 Healthcare 
      Cost and Utilization Project and inflated to 2020 values. Results: The proportion 
      of patients experiencing grade 3/4 AEs decreased over time. Patients who received 
      nivolumab plus ipilimumab had lower average per-patient all-cause grade 3/4 AE 
      costs versus sunitinib (12-month: US$15,170 vs US$20,342; 42-month: US$19,096 vs 
      US$27,473). Conclusion: Treatment with nivolumab plus ipilimumab was associated 
      with lower grade 3/4 AE costs than sunitinib.
FAU - Geynisman, Daniel M
AU  - Geynisman DM
AD  - Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
FAU - Du, Ella X
AU  - Du EX
AD  - Analysis Group, Inc., 333 South Hope Street, Los Angeles, CA 90071, USA.
FAU - Yang, Xiaoran
AU  - Yang X
AD  - Analysis Group, Inc., 333 South Hope Street, Los Angeles, CA 90071, USA.
FAU - Sendhil, Selvam R
AU  - Sendhil SR
AD  - Analysis Group, Inc., 333 South Hope Street, Los Angeles, CA 90071, USA.
FAU - Tejo, Viviana Del
AU  - Tejo VD
AD  - Bristol Myers Squibb, 3551 Lawrenceville Road, Princeton, NJ 08540, USA.
FAU - Betts, Keith A
AU  - Betts KA
AD  - Analysis Group, Inc., 333 South Hope Street, Los Angeles, CA 90071, USA.
FAU - Huo, Stephen
AU  - Huo S
AD  - Bristol Myers Squibb, 3551 Lawrenceville Road, Princeton, NJ 08540, USA.
LA  - eng
GR  - Bristol Myers Squibb/
PT  - Journal Article
DEP - 20211223
PL  - England
TA  - Future Oncol
JT  - Future oncology (London, England)
JID - 101256629
RN  - 0 (Ipilimumab)
RN  - 31YO63LBSN (Nivolumab)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse 
      effects/*economics/therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy
MH  - Cost Savings
MH  - Cost of Illness
MH  - Drug Costs/trends
MH  - Humans
MH  - Ipilimumab/adverse effects/economics/therapeutic use
MH  - Kidney Neoplasms/*drug therapy
MH  - Nivolumab/adverse effects/economics/therapeutic use
MH  - Sunitinib/adverse effects/economics/therapeutic use
OAB - Immunotherapy combinations are now accepted as safe and effective first-line 
      treatment options for advanced or metastatic renal cell carcinoma. This study 
      used patient data from the CheckMate 214 clinical trial to evaluate the temporal 
      trends and costs related to grade 3/4 adverse events (AEs) among patients treated 
      with nivolumab plus ipilimumab versus sunitinib. We found that the proportion of 
      patients experiencing grade 3/4 AEs decreased over time and that patients treated 
      with nivolumab plus ipilimumab had lower AE costs compared with those treated 
      with sunitinib (at 42 months: US$19,096 vs US$27,473 per patient). As such, 
      nivolumab plus ipilimumab may represent a treatment option that may reduce both 
      the clinical and economic burden among patients with advanced or metastatic renal 
      cell carcinoma.
OABL- eng
OTO - NOTNLM
OT  - CheckMate 214
OT  - advanced/metastatic renal cell carcinoma
OT  - adverse events
OT  - costs
OT  - nivolumab plus ipilimumab
OT  - sunitinib
OT  - temporal trends
EDAT- 2021/12/24 06:00
MHDA- 2022/03/24 06:00
CRDT- 2021/12/23 08:39
PHST- 2021/12/24 06:00 [pubmed]
PHST- 2022/03/24 06:00 [medline]
PHST- 2021/12/23 08:39 [entrez]
AID - 10.2217/fon-2021-1109 [doi]
PST - ppublish
SO  - Future Oncol. 2022 Mar;18(10):1219-1234. doi: 10.2217/fon-2021-1109. Epub 2021 
      Dec 23.